Skip to main navigationSkip to main content
The University of Southampton
Southampton Health Technology Assessments CentreNews

New SHTAC report: Bortezomib and thalidomide for the first-line treatment of multiple myeloma

Published: 9 January 2012
New report

A systematic review and economic evaluation of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma, is now available.

The report, published in Health Technology Assessment, was produced by SHTAC to inform a technology appraisal by the National Institute for Health and Clinical Excellence (NICE).  Multiple myeloma is the second most common haematological cancer in the UK but remains an incurable disease. The study found that bortezomib in combination with melphalan and prednisolone/prednisone (VMP), and thalidomide in combination with melphalan and prednisolone/prednisone (MPT), can both be considered more clinically effective than melphalan and prednisolone/prednisone (MP) for the first-line treatment of multiple myeloma in people for whom high-dose therapy and stem cell transplantation would be inappropriate. MPT is more cost-effective than VMP.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×